Biopsy-based management improved the 10-year rate of distant disease-free survival ( hazard ratio for distant metastasis , 0.62 ; P = 0.02 ) and the 10-year rate of melanoma-specific survival ( hazard ratio for death from melanoma , 0.56 ; P = 0.006 ) for patients with intermediate-thickness melanomas and nodal metastases .